drugset / Trial / NCT01822613
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
RandomizedParallel-groupOpen-labelTreatment
Summary
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
Timeline
- Start
- 2013-07-26
- Primary completion
- 2016-06-03
- Completion
- 2016-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 200 mg | Oral |
| Subject | Alpelisib | Small molecule | 400 mg | Oral |
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | ELGEMTUMAB | Monoclonal antibody | 10 mg/kg | — |
| Subject | ELGEMTUMAB | Monoclonal antibody | 40 mg/kg | — |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |